Common genetic variation in TP53 is associated with lung cancer risk and prognosis in African Americans and somatic mutations in lung tumors

Cancer Epidemiology Biomarkers and Prevention

Volumn 16, Issue 2, 2007, Pages 214-222

  Mechanic, Leah E ^a   Bowman, Elise D ^a   Welsh, Judith A ^a   Khan, Mohammed A ^a   Hagiwara, Nobutoshi ^a,b   Enewold, Lindsey ^c   Shields, Peter G ^c   Burdette, Laurie ^d   Chanock, Stephen ^a   Harris, Curtis C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NIPPON MEDICAL SCHOOL HOSPITAL   (Japan)

^c GEORGETOWN UNIVERSITY   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

AFRICAN AMERICAN; AGED; ARTICLE; CANCER RISK; CARCINOGENESIS; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; LUNG CANCER; LUNG TUMOR; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; SOMATIC MUTATION;

AFRICAN AMERICANS; AGED; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; DNA MUTATIONAL ANALYSIS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HUMANS; LOGISTIC MODELS; LUNG NEOPLASMS; MALE; MARYLAND; MIDDLE AGED; POLYMORPHISM, GENETIC; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53; VARIATION (GENETICS);

EID: 33847765747     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-06-0790     Document Type: Article

References (57)

1. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006;24:2137-50.
2. Alberg AJ, Brock MV, Samet JM. Epidemiology of lung cancer: looking to the future. J Clin Oncol 2005;23:3175-85.
3. Schwartz AG, Ruckdeschel JC. Familial lung cancer: genetic susceptibility and relationship to chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006;173:16-22.
4. Liu G, Zhou W, Christiani DC. Molecular epidemiology of non-small cell lung cancer. Semin Respir Crit Care Med 2005;26:265-72.
5. Vahakangas KH, Samet JM, Metcalf RA, et al. Mutations of p53 and ras genes in radon-associated lung cancer from uranium miners. Lancet 1992;339:576-80.
6. Bennett WP, Colby TV, Travis WD, et al. p53 protein accumulates frequently in early bronchial neoplasia. Cancer Res 1993;53:4817-22.
7. Nigro JM, Baker SJ, Preisinger AC, et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 1989;342:705-8.
8. Takahashi T, Nau MM, Chiba I, et al. p53: a frequent target for genetic abnormalities in lung cancer. Science 1989;246:491-4.
9. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53.
10. Oren M. Decision making by p53: life, death, and cancer. Cell Death Differ 2003;10:431-42.
11. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000;408:307-10.
12. Lane D. Anthony Dipple Carcinogenesis Award. p53 from pathway to therapy. Carcinogenesis 2004;25:1077-81.
13. Tammemagi MC, McLaughlin JR, Bull SB. Meta-analyses of p53 tumor suppressor gene alterations and clinicopathological features in resected lung cancers. Cancer Epidemiol Biomarkers Prev 1999;8:625-34.
14. Yokota J, Kohno T. Molecular footprints of human lung cancer progression. Cancer Sci 2004;95:197-204.
15. Vousden KH. p53: death star. Cell 2000;103:691-4.
16. Pfeifer GP, Denissenko MF, Olivier M, et al. Tobacco smoke carcinogens, DNA damage, and p53 mutations in smoking-associated cancers. Oncogene 2002;21:7435-51.
17. Murphy ME. Polymorphic variants in the p53 pathway. Cell Death Differ 2006;13:916-20.
18. Pietsch EC, Humbey O, Murphy ME. Polymorphisms in the p53 pathway. Oncogene 2006;25:1602-11.
19. Matakidou A, Eisen T, Houlston RS. TP53 polymorphisms and lung cancer risk: a systematic review and meta-analysis. Mutagenesis 2003;18:377-85.
20. Dumont P, Leu JI, Della Pietra AC III, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 2003;33:357-65.
21. Sullivan A, Syed N, Gasco M, et al. Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. Oncogene 2004;23:3328-37.
22. Pim D, Banks L. p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer 2004;108:196-9.
23. Siddique M, Sabapathy K. Trp53-dependent DNA-repair is affected by the codon 72 polymorphism. Oncogene 2006;25:3489-500.
24. Mechanic LE, Marrogi AJ, Welsh JA, et al. Polymorphisms in XPD and TP53 and mutation in human lung cancer. Carcinogenesis 2005;26:597-604.
25. Zheng YL, Loffredo CA, Yu Z, et al. Bleomycin-induced chromosome breaks as a risk marker for lung cancer: a case-control study with population and hospital controls. Carcinogenesis 2003;24:269-74.
26. Zheng YL, Loffredo CA, Alberg AJ, et al. Less efficient g2-m checkpoint is associated with an increased risk of lung cancer in African Americans. Cancer Res 2005;65:9566-73.
27. Packer BR, Yeager M, Burdett L, et al. SNP500Cancer: a public resource for sequence validation, assay development, and frequency analysis for genetic variation in candidate genes. Nucleic Acids Res 2006;34:D617-21.
28. Johnson GC, Esposito L, Barratt BJ, et al. Haplotype tagging for the identification of common disease genes. Nat Genet 2001;29:233-7.
29. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001;68:978-89.
30. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005;21:263-5.
31. Gabriel SB, Schaffner SF, Nguyen H, et al. The structure of haplotype blocks in the human genome. Science 2002;296:2225-9.
32. Schaid DJ. Evaluating associations of haplotypes with traits. Genet Epidemiol 2004;27:348-64.
33. Tregouet DA, Tiret L. Cox proportional hazards survival regression in haplotype-based association analysis using the Stochastic-EM algorithm. Eur J Hum Genet 2004;12:971-4.
34. Marrogi AJ, Mechanic LE, Welsh JA, et al. TP53 mutation spectrum in lung cancer is not different in women and men. Cancer Epidemiol Biomarkers Prev 2005;14:1031-3.
35. Weston A, Pan CF, Ksieski HB, et al. p53 haplotype determination in breast cancer. Cancer Epidemiol Biomarkers Prev 1997;6:105-12.
36. Weston A, Ling-Cawley HM, Caporaso NE, et al. Determination of the allelic frequencies of an L-myc and a p53 polymorphism in human lung cancer. Carcinogenesis 1994;15:583-7.
37. Wu X, Zhao H, Amos CI, et al. p53 genotypes and haplotypes associated with lung cancer susceptibility and ethnicity. J Natl Cancer Inst 2002;94:681-90.
38. Liu G, Miller DP, Zhou W, et al. Differential association of the codon 72 p53 and GSTM1 polymorphisms on histological subtype of non-small cell lung carcinoma. Cancer Res 2001;61:8718-22.
39. Birgander R, Sjalander A, Rannug A, et al. P53 polymorphisms and haplotypes in lung cancer. Carcinogenesis 1995;16:2233-6.
40. Shen H, Zheng Y, Sturgis EM, Spitz MR, Wei Q. P53 codon 72 polymorphism and risk of squamous cell carcinoma of the head and neck: a case-control study. Cancer Lett 2002;183:123-30.
41. Miller DP, Liu G, De Vivo I, et al. Combinations of the variant genotypes of GSTP1, GSTM1, and p53 are associated with an increased lung cancer risk. Cancer Res 2002;62:2819-23.
42. Pierce LM, Sivaraman L, Chang W, et al. Relationships of TP53 codon 72 and HRAS1 polymorphisms with lung cancer risk in an ethnically diverse population. Cancer Epidemiol Biomarkers Prev 2000;9:1199-204.
43. Wirtenberger M, Frank B, Hemminki K, et al. Interaction of Werner and Bloom syndrome genes with p53 in familial breast cancer. Carcinogenesis 2006;27:1655-60.
44. Mitra S, Sikdar N, Misra C, et al. Risk assessment of p53 genotypes and haplotypes in tobacco-associated leukoplakia and oral cancer patients from eastern Idia. Int J Cancer 2005;117:786-93.
45. Khrunin AV, Tarskaia LA, Spitsyn VA, et al. p53 polymorphisms in Russia and Belarus: correlation of the 2-1-1 haplotype frequency with longitude. Mol Genet Genomics 2005;272:666-72.
46. Schabath MB, Wu X, Wei Q, et al. Combined effects of the p53 and p73 polymorphisms on lung cancer risk. Cancer Epidemiol Biomarkers Prev 2006;15:158-61.
47. Hong Y, Miao X, Zhang X, et al. The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. Cancer Res 2005;65:9582-7.
48. Zhang X, Miao X, Guo Y, et al. Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer. Hum Mutat 2006;27:110-7.
49. Giovino GA, Sidney S, Gfroerer JC, et al. Epidemiology of menthol cigarette use. Nicotine Tob Res 2004;6 Suppl 1:S67-81.
50. McCarthy WJ, Caskey NH, Jarvik ME, et al. Menthol vs nonmenthol cigarettes: effects on smoking behavior. Am J Public Health 1995;85:67-72.
51. Felley-Bosco E, Weston A, Cawley HM, Bennett WP, Harris CC. Functional studies of a germ-line polymorphism at codon 47 within the p53 gene. Am J Hum Genet 1993;53:752-9.
52. Li X, Dumont P, Della Pietra A, Shetler C, Murphy ME. The codon 47 polymorphism in p53 is functionally significant. J Biol Chem 2005;280:24245-51.
53. Fan R, Wu MT, Miller D, et al. The p53 codon 72 polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev 2000;9:1037-42.
54. Jin X, Wu X, Roth JA, et al. Higher lung cancer risk for younger African-Americans with the Pro/Pro p53 genotype. Carcinogenesis 1995;16:2205-8.
55. Weston A, Perrin LS, Forrester K, et al. Allelic frequency of a p53 polymorphism in human lung cancer. Cancer Epidemiol Biomarkers Prev 1992;1:481-3.
56. Greenblatt MS, Beaudet JG, Gump JR, et al. Detailed computational study of p53 and p16: using evolutionary sequence analysis and disease-associated mutations to predict the functional consequences of allelic variants. Oncogene 2003;22:1150-63.
57. Bonnen PE, Wang PJ, Kimmel M, Chakraborty R, Nelson DL. Haplotype and linkage disequilibrium architecture for human cancer-associated genes. Genome Res 2002;12:1846-53.